Drugs makers to be watched by European Commission
The European Commission will intensify scrutiny of the pharmaceutical industry under antitrust law and monitor originator-generic settlements, it said in a report published today
The Commissions report is the culmination of a 18-month sector inquiry into why fewer new medicines are brought to the market and why generic entry can be delayed.
The Commission said it will monitor the industry under EU...
Please log in
to read the rest of this article. New to Managing Intellectual Property?
Take advantage of free access to up to 5 articles on Managing IP and become a member today. It’s free to join and the benefits start straight away.
Please make sure you log in to read the rest of the article.
Join us nowGain FREE access to up to five free articles when you register now.